Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer

This study aims to evaluate the clinical value of circulating tumor DNA (ctDNA) as a minimally invasive biomarker for monitoring treatment response and guiding systemic therapy in patients with gastric or gastroesophageal junction adenocarcinoma. Gastric cancer is often diagnosed at an advanced stage and shows substantial biological heterogeneity. Current treatment decisions mainly rely on imaging and clinical assessment, which may not reflect early molecular changes or minimal residual disease. Circulating tumor DNA, released from tumor cells into the bloodstream, can provide real-time infor

Trial Details

NCT ID
NCT07517107
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Circulating Tumor DNA (ctDNA) Analysis
  • Standard Systemic Therapy for Gastric Cancer
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥18 years. Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Adequate organ function within 7 days prior to enrollment, including:
  • Absolute neutrophil count ≥1.5 × 10⁹/L Platelet count ≥80 × 10⁹/L Hemoglobin ≥80 g/L Total bilirubin ≤1.5 × upper limit of normal (ULN) AST and ALT…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →